Azithromycin before anti-TNF treatment for Crohn’s disease
Treatments studied
Part of Digestive system clinical trials.
This Phase 2 trial tests whether taking azithromycin (an antibiotic) before starting infliximab or adalimumab can reduce the chance your body rejects the anti‑TNF medicine. It may help some people get better and keep responding to treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18–80 and can sign consent and attend all study visits.
- You have Crohn’s disease (symptoms for at least 3 months) and are starting infliximab or adalimumab.
- You cannot be enrolled in another experimental (interventional) study at the same time.
- You must not be on long-term antibiotics, and you should not have taken antibiotics in the last 4 weeks.
- You should be able to take the study antibiotic as planned (no azithromycin allergy, and not pregnant).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two medicine options (azathioprine vs methotrexate) when added to adalimumab to treat active Crohn’s disease. It may help determine which add-on works better for people whose Crohn’s is still active despite standard treatments or who can’t take them.
This study tests whether giving a steroid (dexamethasone) before an infliximab infusion can prevent allergic reactions in people with moderate-to-severe Crohn's disease or ulcerative colitis. If you qualify, you will receive either the steroid or a placebo before your infliximab treatment.
This study is testing whether adding a probiotic (Bacillus subtilis) to standard infliximab treatment can improve outcomes for people with active Crohn's disease. It aims to see if the probiotic helps the medication work better.
This study tests a combination of two drugs, infliximab and azathioprine, to see if it works better than either drug alone for children with moderate to severe Crohn's disease. The trial is for children who have not used these drugs before.
This trial tests whether people with Crohn’s disease or ulcerative colitis who are currently well-controlled can safely use less-frequent anti-TNF medicine. It may help reduce treatment intensity while keeping inflammation under control.
This trial tests a special diet (CDED) combined with anti-TNF medication (infliximab or adalimumab) to see if it's safe and works better for active Crohn's disease. It may help if you haven't used these drugs before and can follow the diet.
Hear when a new Crohn's Disease Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.